Curis, Inc.
(NASDAQ : CRIS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -3.52%75.700.0%$2400.05m
NVAXNovavax, Inc. 10.33%173.4199.2%$1287.55m
GILDGilead Sciences, Inc. -2.31%69.241.0%$527.60m
AMGNAmgen, Inc. -1.10%240.911.3%$509.95m
REGNRegeneron Pharmaceuticals, Inc. -3.41%626.332.5%$459.38m
SRNESorrento Therapeutics, Inc. 6.91%13.731.8%$446.16m
BNTXBioNTech SE -2.48%81.110.0%$402.65m
VRTXVertex Pharmaceuticals, Inc. -1.42%271.811.9%$379.14m
BIIBBiogen, Inc. -0.21%275.511.6%$326.25m
ILMNIllumina, Inc. 1.75%400.583.5%$325.55m
VXRTVaxart, Inc. 8.60%9.660.0%$325.14m
IBIOiBio, Inc. -0.11%4.391.8%$182.64m
EBSEmergent BioSolutions, Inc. 9.56%134.356.4%$177.28m
SGENSeattle Genetics, Inc. -1.71%162.246.1%$172.11m
ALXNAlexion Pharmaceuticals, Inc. -2.36%102.742.0%$170.84m

Company Profile

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.